Sign in with Google
bearish
Endo International (ENDP US): Still in Troubled Waters; No Near-Term Growth Driver Is Seen
361 Views09 Jun 2022 13:19
SUMMARY
- Endo International (ENDP US) shares are trading near their lows. However, Endo does not seem to be an attractive bottom fishing idea as opioid litigation is still the major overhang.
- Endo’s top selling drug Vasostrict is facing generic competition, which has dragged Q1 performance of the company. Q1 revenue declined 9%, while Q2 revenue is expected to decline 28%.
- Endo is banking on specialty branded drug Xiaflex and QWO, and sterile injectables for its long-term growth. However, they cannot fully offset the impact of Vasostrict revenue loss in near-term.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- NTT (9432) To Overpay To Take Over NTT Data (9613) Subsidiary?
- Laopu Gold (6181 HK): US$300m Primary Placement & Index Inclusion Green Light
- CATL (300750 CH): Index Inclusion as Potential Listing Nears
- Errors in Local Street's Projections for the KOSPI 200 Rebalancing
- Pre-IPO Auntea Jenny (Shanghai) Industrial (PHIP Updates) - Some Points Worth the Attention
Top Unpaywalled Insights
More »- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
- The Evolution of Portfolio Management: Bridging Traditional Models and Machine Learning
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Endo International (ENDP US): Still in Troubled Waters; No Near-Term Growth Driver Is Seen09 Jun 2022
x